# A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

> **NCT00402233** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 312 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Pramipexole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00402233
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402233, "A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00402233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*